Washington has never before been so focused on lowering prescription drug prices. But these biotech investors aren’t worried.
“Politics is politics,” Affinity Asset Advisors senior research analyst Patrick Nosker said of drug pricing legislation at a STAT event Tuesday in New York. “The whole political overhang is definitely going to be noise throughout the next year.”
About the Author Reprints
